NCT05619978View on ClinicalTrials.gov

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Chronic Myeloid Leukemia
Interventions
OTHER

3L Therapy

Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT

OTHER

T315I

Patients with chronic myeloid leukemia with T315I mutation

Trial Locations (1)

Unknown

Novartis Investigative Site, Lyon

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY